REGN

Regeneron Pharmaceuticals Inc.

Price

$755.51

return (12m)

p/e

15.93

p/bv

2.24

DIVIDEND YIELD

0.54%

REGN price

Regeneron Pharmaceuticals

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment REGN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals REGN

Valuation

P/E

15.93

Sector -4.15

Industry -4.15

P/BV

2.24

Sector 2.06

Industry 2.06

P/Revenue (PSR)

4.72

Sector -4.16

Industry -4.16

EV/EBITDA

65.85

Sector -241.86

Industry -241.86

EV/EBIT

75.46

Sector -671.75

Industry -671.75

P/EBITDA

12.27

Sector -4.30

Industry -4.30

P/EBIT

13.54

Sector -4.35

Industry -4.35

P/Total Assets

1.72

Sector 1.46

Industry 1.46

P/Net Current Assets

8.04

Sector -12.67

Industry -12.67

P/Working Capital

5.38

Sector -12.58

Industry -12.58

EPS

42.53

Sector -2.19

Industry -2.19

BVPS

302.15

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

84.55%

Sector 36.44%

Industry 36.44%

EBITDA Margin

26.83%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

23.41%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

25.76%

Sector -38.78%

Industry -38.78%

Net Profit Margins

29.65%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.09

Sector 0.03

Industry 0.03

Profitability

ROE

14.08%

Sector -67.01%

Industry -67.01%

ROA

10.82%

Sector -66.28%

Industry -66.28%

ROIC

9.23%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.54%

Sector -

Industry -

Payout

8.60%

Sector -

Industry -

Debt

Current Ratio

3.57

Sector 2.90

Industry 2.90

Net Debt / EBITDA

-7.00

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

-8.02

Sector -3.79

Industry -3.79

Net Debt / Equity

-0.22

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.06

Sector 0.00

Industry 0.00

Equity/Assets

0.77

Sector 0.42

Industry 0.42

Liabilities/Assets

0.23

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-1.48%

Sector -

Industry -

5Y Earnings CAGR

-11.34%

Sector -

Industry -

FAIR VALUE OF Regeneron Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$755.51

Fair Value

$537.71

Upside Return potential.

-28.83%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals REGN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
REGN Regeneron Pharmaceuticals Inc.	$755.51	37.07%	0.54%	15.93	2.24	14.08%	29.65%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

REGN Historical Dividends

current DY: 0.54%

5-year average DY: 0.34%

DRAG THE FRAME TO SEE MORE DATA

type	Ex - Dividend Date	payment date	value
Dividends	02/20/2026	03/05/2026	0.94000000
Dividends	11/20/2025	12/05/2025	0.88000000
Dividends	08/18/2025	09/03/2025	0.88000000
Dividends	05/20/2025	06/06/2025	0.88000000
Dividends	02/20/2025	03/20/2025	0.88000000

ABOUT Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

38 years

Founded: 1988

1991

Time since IPO - 35 years

9.123

Employees

Regeneron Pharmaceuticals Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $70.47 billion, with shareholders equity totaling $31.42 billion.

The company employs approximately 9.123 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, Regeneron Pharmaceuticals Inc. reported $14.92 billion in revenue, generating net income of $4.42 billion.

Key financial metrics include a P/E ratio of 15.93, a price-to-book (P/B) ratio of 2.24, and a trailing twelve-month dividend yield of 0.54%.

The company trades under the ticker REGN.

Market cap

$70.47 billion

Net worth

$31.42 billion

$31,423,600,000.00

Assets

$40.87 billion

$40,868,800,000.00

Total Shares Outstanding

104.00 million

104,000,000

Average Daily Trading Volume

$1.05 million

$1,047,236.00

Sector

Healthcare

Industry

Biotecnologia

REGN

revenue by Business Segment Regeneron Pharmaceuticals

REGN revenue and profits

Financial Results REGN

DRAG THE FRAME TO SEE MORE DATA

REGN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14